{
  "url": "https://finance.yahoo.com/news/phillips-66s-nyse-psx-impressive-110030570.html?_guc_consent_skip=1756379880",
  "authorsByline": "Simply Wall St",
  "articleId": "1421765c6a254512bd8b73cb0ffe201c",
  "source": {
    "domain": "finance.yahoo.com",
    "location": {
      "country": "us",
      "state": "CA",
      "county": "Santa Clara County",
      "city": "Sunnyvale",
      "coordinates": {
        "lat": 37.3688301,
        "lon": -122.036349
      }
    }
  },
  "imageUrl": "https://media.zenfs.com/en/simply_wall_st__316/3a7514e97bfd657fa693ec721eb25f21",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-28T11:00:30+00:00",
  "addDate": "2025-08-28T11:20:17.794892+00:00",
  "refreshDate": "2025-08-28T11:20:17.794893+00:00",
  "score": 1.0,
  "title": "Has Phillips 66's (NYSE:PSX) Impressive Stock Performance Got Anything to Do With Its Fundamentals?",
  "description": "Phillips 66's (NYSE:PSX) stock is up by a considerable 17% over the past three months. As most would know, fundamentals...",
  "content": "Phillips 66's (NYSE:PSX) stock is up by a considerable 17% over the past three months. As most would know, fundamentals are what usually guide market price movements over the long-term, so we decided to look at the company's key financial indicators today to determine if they have any role to play in the recent price movement. In this article, we decided to focus on Phillips 66's ROE. Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Simply put, it is used to assess the profitability of a company in relation to its equity capital. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Return on equity can be calculated by using the formula: So, based on the above formula, the ROE for Phillips 66 is: 6.4% = US$1.8b \u00f7 US$29b (Based on the trailing twelve months to June 2025). The 'return' refers to a company's earnings over the last year. So, this means that for every $1 of its shareholder's investments, the company generates a profit of $0.06. Why Is ROE Important For Earnings Growth? So far, we've learned that ROE is a measure of a company's profitability. We now need to evaluate how much profit the company reinvests or \"retains\" for future growth which then gives us an idea about the growth potential of the company. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features. A Side By Side comparison of Phillips 66's Earnings Growth And 6.4% ROE At first glance, Phillips 66's ROE doesn't look very promising. We then compared the company's ROE to the broader industry and were disappointed to see that the ROE is lower than the industry average of 11%. However, we we're pleasantly surprised to see that Phillips 66 grew its net income at a significant rate of 30% in the last five years. Therefore, there could be other reasons behind this growth. For instance, the company has a low payout ratio or is being managed efficiently. As a next step, we compared Phillips 66's net income growth with the industry and found that the company has a similar growth figure when compared with the industry average growth rate of 32% in the same period.\n\nThe basis for attaching value to a company is, to a great extent, tied to its earnings growth. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. This then helps them determine if the stock is placed for a bright or bleak future. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if Phillips 66 is trading on a high P/E or a low P/E, relative to its industry. Is Phillips 66 Making Efficient Use Of Its Profits? Phillips 66 has a three-year median payout ratio of 31% (where it is retaining 69% of its income) which is not too low or not too high. This suggests that its dividend is well covered, and given the high growth we discussed above, it looks like Phillips 66 is reinvesting its earnings efficiently. Additionally, Phillips 66 has paid dividends over a period of at least ten years which means that the company is pretty serious about sharing its profits with shareholders. Our latest analyst data shows that the future payout ratio of the company is expected to rise to 39% over the next three years. Still, forecasts suggest that Phillips 66's future ROE will rise to 17% even though the the company's payout ratio is expected to rise. We presume that there could some other characteristics of the business that could be driving the anticipated growth in the company's ROE. On the whole, we do feel that Phillips 66 has some positive attributes. Despite its low rate of return, the fact that the company reinvests a very high portion of its profits into its business, no doubt contributed to its high earnings growth. Having said that, the company's earnings growth is expected to slow down, as forecasted in the current analyst estimates. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.\n\n\n\nThis article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.",
  "medium": "Article",
  "links": [
    "https://simplywall.st/company/id/15E05696-3826-44C3-B624-607CEF9CF46E/valuation?blueprint=4022332&utm_medium=finance_user&utm_campaign=conclusion&utm_source=yahoo",
    "https://simplywall.st/company/id/15E05696-3826-44C3-B624-607CEF9CF46E/past?blueprint=4022332&amp;utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo",
    "https://simplywall.st/company/id/15E05696-3826-44C3-B624-607CEF9CF46E?blueprint=4022332&utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo",
    "https://au.finance.yahoo.com/quote/PSX",
    "https://simplywall.st/discover/investing-ideas/434426/us-transformative-artificial-intelligence-ai-healthcare-stocks/global?blueprint=4022332&utm_medium=finance_user&utm_campaign=investing-ideas&utm_source=yahoo&utm_content=ai-healthcare",
    "https://simplywall.st/company/id/15E05696-3826-44C3-B624-607CEF9CF46E/future?blueprint=4022332&utm_medium=finance_user&utm_campaign=conclusion&utm_source=yahoo"
  ],
  "labels": [
    {
      "name": "Non-news"
    }
  ],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "Phillips 66",
      "weight": 0.10434162
    },
    {
      "name": "expected earnings growth",
      "weight": 0.09759724
    },
    {
      "name": "companies",
      "weight": 0.09616916
    },
    {
      "name": "Earnings Growth",
      "weight": 0.09604979
    },
    {
      "name": "future growth",
      "weight": 0.083500415
    },
    {
      "name": "Phillips",
      "weight": 0.07872911
    },
    {
      "name": "Phillips 66s Earnings Growth",
      "weight": 0.07676199
    },
    {
      "name": "Phillips 66s net income growth",
      "weight": 0.07319894
    },
    {
      "name": "higher profit retention",
      "weight": 0.06917789
    },
    {
      "name": "Phillips 66s future ROE",
      "weight": 0.06743432
    }
  ],
  "topics": [
    {
      "name": "Stocks"
    },
    {
      "name": "Markets"
    }
  ],
  "categories": [
    {
      "name": "Finance"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.98388671875
    },
    {
      "name": "/News/Business News/Company News",
      "score": 0.97998046875
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.97607421875
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.7802734375
    }
  ],
  "sentiment": {
    "positive": 0.3510173,
    "negative": 0.16508177,
    "neutral": 0.48390102
  },
  "summary": "Phillips 66's (NYSE:PSX) stock has risen by 17% over the past three months. The company's Return on Equity (ROE) is an important factor to consider as a key financial indicator to determine how effectively their capital is being reinvested. The ROE is used to assess the profitability of a company in relation to its equity capital. For example, for every $1 of its shareholder's investments, the company generates a profit of $0.06. However, the ROE for Phillips 66 is lower than the industry average of 11%. This growth figure could be attributed to the company's low payout ratio or efficient management. Despite this, forecasts suggest that the future ROE will rise to 17% and the expected growth rate is expected to slow as forecasted.",
  "shortSummary": "Phillips 66's impressive stock performance may have been driven by its high ROE and dividend sustainability, but analysts warn this may also influence future earnings growth.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": false,
  "reprintGroupId": "08734bc84a6a41a090576c2b8f5ef00e",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://simplywall.st/company/id/15E05696-3826-44C3-B624-607CEF9CF46E/future?blueprint=4022332&utm_medium=finance_user&utm_campaign=conclusion&utm_source=yahoo",
      "text": "Phillips 66 Future Growth\nFuture criteria checks 3/6\nPhillips 66's revenue is forecast to decline at 3% per annum while its annual earnings are expected to grow at 22.5% per year. EPS is expected to grow by 24.3% per annum. Return on equity is forecast to be 16.8% in 3 years.\nKey information\n22.5%\nEarnings growth rate\n24.35%\nEPS growth rate\n| Oil and Gas earnings growth | 13.3% |\n| Revenue growth rate | -3.0% |\n| Future return on equity | 16.77% |\n| Analyst coverage | Good |\n| Last updated | 17 Aug 2025 |\nRecent future growth updates\nRecent updates\nPhillips 66: The Trajectory Is Improving\nAug 15Phillips 66 (NYSE:PSX) Might Be Having Difficulty Using Its Capital Effectively\nAug 14Phillips 66's (NYSE:PSX) Shareholders Will Receive A Bigger Dividend Than Last Year\nMay 06Weak Statutory Earnings May Not Tell The Whole Story For Phillips 66 (NYSE:PSX)\nMay 05With A 26% Price Drop For Phillips 66 (NYSE:PSX) You'll Still Get What You Pay For\nApr 09room for higher margins\nIndustry Position: Phillips 66 is a major player in the energy sector, particularly in refining, marketing, and transportation. Analysts often look at the company's ability to capitalize on operationaElliott Management Applies Pressure With Phillips 66 Board Fight\nMar 26Phillips 66: Ignore Elliott Management\nFeb 25Phillips 66 Just Missed Earnings - But Analysts Have Updated Their Models\nFeb 04Philips 66: Refining Hurts Q4, But Long-Term Value Remains\nFeb 01Phillips 66 Makes An Intelligent Acquisition Of EPIC NGL\nJan 13Phillips 66: Bottom Fishing At The Bottom Of The Refining Cycle (Rating Upgrade)\nDec 25Phillips 66: Refiners Are 'Deer In The Headlights' Of Canadian Import Tariffs\nDec 07Phillips 66: 3.4% Yield, Consistent Dividend Growth, Cheap\nOct 24Phillips 66 Is Expanding Past Its Refining Roots\nOct 18Are Investors Undervaluing Phillips 66 (NYSE:PSX) By 44%?\nOct 17Strategically Envisioning A Greener Future Through Innovative Energy Solutions And Financial Resilience\nTransition to producing renewable fuels at the Rodeo Renewable Energy Complex aims to meet growing demand for environmentally friendly energy options.These 4 Measures Indicate That Phillips 66 (NYSE:PSX) Is Using Debt Extensively\nSep 16The Value Of Phillips 66's Midstream Assets Shine Bright In 2024\nAug 01Phillips 66: Sell-Off Creates Opportunity, Given Likely Q2 Acceleration (Rating Upgrade)\nJul 12Phillips 66: Turnaround Still Very Much A Work In Progress\nApr 29Earnings and Revenue Growth Forecasts\n| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |\n|---|---|---|---|---|---|\n| 12/31/2027 | 128,506 | 5,149 | 5,218 | 6,510 | 7 |\n| 12/31/2026 | 126,486 | 3,783 | 3,955 | 6,143 | 10 |\n| 12/31/2025 | 132,291 | 2,949 | 4,141 | 4,627 | 10 |\n| 6/30/2025 | 132,966 | 1,708 | 1,488 | 3,362 | N/A |\n| 3/31/2025 | 137,772 | 1,846 | 2,960 | 4,614 | N/A |\n| 12/31/2024 | 143,153 | 2,107 | 2,332 | 4,191 | N/A |\n| 9/30/2024 | 147,738 | 3,358 | 2,933 | 5,183 | N/A |\n| 6/30/2024 | 151,853 | 5,110 | 4,515 | 6,736 | N/A |\n| 3/31/2024 | 148,814 | 5,792 | 3,189 | 5,594 | N/A |\n| 12/31/2023 | 147,399 | 7,004 | 4,874 | 7,029 | N/A |\n| 9/30/2023 | 149,408 | 7,629 | 7,355 | 9,589 | N/A |\n| 6/30/2023 | 154,720 | 10,922 | 7,671 | 10,048 | N/A |\n| 3/31/2023 | 168,207 | 12,392 | 8,674 | 10,876 | N/A |\n| 12/31/2022 | 169,990 | 11,014 | 8,925 | 10,813 | N/A |\n| 9/30/2022 | 162,315 | 10,403 | 5,785 | 7,863 | N/A |\n| 6/30/2022 | 147,603 | 5,416 | 5,027 | 6,922 | N/A |\n| 3/31/2022 | 126,028 | 2,543 | 4,983 | 6,882 | N/A |\n| 12/31/2021 | 111,476 | 1,306 | 4,157 | 6,017 | N/A |\n| 9/30/2021 | 95,242 | -506 | 3,087 | 4,856 | N/A |\n| 6/30/2021 | 80,948 | -1,708 | 1,375 | 3,144 | N/A |\n| 3/31/2021 | 64,881 | -2,142 | -163 | 2,165 | N/A |\n| 12/31/2020 | 64,129 | -3,983 | -809 | 2,111 | N/A |\n| 9/30/2020 | 76,863 | -2,707 | -526 | 3,166 | N/A |\n| 6/30/2020 | 88,148 | -1,196 | 330 | 4,337 | N/A |\n| 3/31/2020 | 105,083 | 369 | 1,804 | 5,503 | N/A |\n| 12/31/2019 | 107,293 | 3,070 | 935 | 4,808 | N/A |\n| 9/30/2019 | 107,330 | 4,573 | 3,664 | 7,253 | N/A |\n| 6/30/2019 | 109,884 | 5,354 | 2,672 | 6,173 | N/A |\n| 3/31/2019 | 110,994 | 5,270 | N/A | 6,607 | N/A |\n| 12/31/2018 | 111,492 | 5,589 | N/A | 7,573 | N/A |\n| 9/30/2018 | 108,719 | 6,547 | N/A | 5,365 | N/A |\n| 6/30/2018 | 101,182 | 5,878 | N/A | 5,184 | N/A |\n| 3/31/2018 | 93,037 | 5,088 | N/A | 4,685 | N/A |\n| 12/31/2017 | 89,300 | 5,100 | N/A | 3,648 | N/A |\n| 9/30/2017 | 83,177 | 2,066 | N/A | 2,384 | N/A |\n| 6/30/2017 | 79,209 | 1,753 | N/A | 2,866 | N/A |\n| 3/31/2017 | 76,725 | 1,699 | N/A | 2,156 | N/A |\n| 12/31/2016 | 70,898 | 1,549 | N/A | 2,963 | N/A |\n| 9/30/2016 | 69,143 | 2,036 | N/A | 3,793 | N/A |\n| 6/30/2016 | 73,139 | 3,103 | N/A | 4,347 | N/A |\n| 3/31/2016 | 79,837 | 3,620 | N/A | 4,619 | N/A |\n| 12/31/2015 | 85,228 | 4,221 | N/A | 5,713 | N/A |\n| 9/30/2015 | 98,055 | 4,717 | N/A | 5,088 | N/A |\n| 6/30/2015 | 112,412 | 4,319 | N/A | 4,080 | N/A |\n| 3/31/2015 | 129,169 | 4,169 | N/A | 3,483 | N/A |\n| 12/31/2014 | 146,514 | 4,049 | N/A | 3,529 | N/A |\n| 9/30/2014 | 154,640 | 3,711 | N/A | 3,554 | N/A |\nAnalyst Future Growth Forecasts\nEarnings vs Savings Rate: PSX's forecast earnings growth (22.5% per year) is above the savings rate (3.1%).\nEarnings vs Market: PSX's earnings (22.5% per year) are forecast to grow faster than the US market (15.1% per year).\nHigh Growth Earnings: PSX's earnings are expected to grow significantly over the next 3 years.\nRevenue vs Market: PSX's revenue is expected to decline over the next 3 years (-3% per year).\nHigh Growth Revenue: PSX's revenue is forecast to decline over the next 3 years (-3% per year).\nEarnings per Share Growth Forecasts\nFuture Return on Equity\nFuture ROE: PSX's Return on Equity is forecast to be low in 3 years time (16.8%).\nDiscover growth companies\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/28 07:41 |\n| End of Day Share Price | 2025/08/27 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nPhillips 66 is covered by 36 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| William Selesky | Argus Research Company |\n| Yim Cheng | Barclays |\n| Theresa Chen | Barclays |"
    },
    {
      "url": "https://simplywall.st/company/id/15E05696-3826-44C3-B624-607CEF9CF46E?blueprint=4022332&utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo",
      "text": "Phillips 66 (PSX) Stock Overview\nOperates as an energy manufacturing and logistics company in the United States, the United Kingdom, Germany, and internationally. More details\n| Snowflake Score | |\n|---|---|\n| Valuation | 2/6 |\n| Future Growth | 3/6 |\n| Past Performance | 2/6 |\n| Financial Health | 1/6 |\n| Dividends | 3/6 |\nPSX Community Fair Values\nSee what 56 others think this stock is worth. Follow their fair value or set your own to get alerts.\nPhillips 66 Competitors\nPrice History & Performance\n| Historical stock prices | |\n|---|---|\n| Current Share Price | US$132.62 |\n| 52 Week High | US$140.85 |\n| 52 Week Low | US$91.01 |\n| Beta | 1.06 |\n| 1 Month Change | 3.28% |\n| 3 Month Change | 16.87% |\n| 1 Year Change | -2.84% |\n| 3 Year Change | 53.62% |\n| 5 Year Change | 122.18% |\n| Change since IPO | 290.06% |\nRecent News & Updates\nPhillips 66: The Trajectory Is Improving\nAug 15Phillips 66 (NYSE:PSX) Might Be Having Difficulty Using Its Capital Effectively\nAug 14Recent updates\nPhillips 66: The Trajectory Is Improving\nAug 15Phillips 66 (NYSE:PSX) Might Be Having Difficulty Using Its Capital Effectively\nAug 14Phillips 66's (NYSE:PSX) Shareholders Will Receive A Bigger Dividend Than Last Year\nMay 06Weak Statutory Earnings May Not Tell The Whole Story For Phillips 66 (NYSE:PSX)\nMay 05With A 26% Price Drop For Phillips 66 (NYSE:PSX) You'll Still Get What You Pay For\nApr 09room for higher margins\nIndustry Position: Phillips 66 is a major player in the energy sector, particularly in refining, marketing, and transportation. Analysts often look at the company's ability to capitalize on operationaElliott Management Applies Pressure With Phillips 66 Board Fight\nMar 26Phillips 66: Ignore Elliott Management\nFeb 25Phillips 66 Just Missed Earnings - But Analysts Have Updated Their Models\nFeb 04Philips 66: Refining Hurts Q4, But Long-Term Value Remains\nFeb 01Phillips 66 Makes An Intelligent Acquisition Of EPIC NGL\nJan 13Phillips 66: Bottom Fishing At The Bottom Of The Refining Cycle (Rating Upgrade)\nDec 25Phillips 66: Refiners Are 'Deer In The Headlights' Of Canadian Import Tariffs\nDec 07Phillips 66: 3.4% Yield, Consistent Dividend Growth, Cheap\nOct 24Phillips 66 Is Expanding Past Its Refining Roots\nOct 18Are Investors Undervaluing Phillips 66 (NYSE:PSX) By 44%?\nOct 17Strategically Envisioning A Greener Future Through Innovative Energy Solutions And Financial Resilience\nTransition to producing renewable fuels at the Rodeo Renewable Energy Complex aims to meet growing demand for environmentally friendly energy options.These 4 Measures Indicate That Phillips 66 (NYSE:PSX) Is Using Debt Extensively\nSep 16The Value Of Phillips 66's Midstream Assets Shine Bright In 2024\nAug 01Phillips 66: Sell-Off Creates Opportunity, Given Likely Q2 Acceleration (Rating Upgrade)\nJul 12Phillips 66: Turnaround Still Very Much A Work In Progress\nApr 29Shareholder Returns\n| PSX | US Oil and Gas | US Market | |\n|---|---|---|---|\n| 7D | 6.6% | 3.4% | 1.9% |\n| 1Y | -2.8% | 1.1% | 17.5% |\nReturn vs Industry: PSX underperformed the US Oil and Gas industry which returned 1.1% over the past year.\nReturn vs Market: PSX underperformed the US Market which returned 17.5% over the past year.\nPrice Volatility\n| PSX volatility | |\n|---|---|\n| PSX Average Weekly Movement | 3.7% |\n| Oil and Gas Industry Average Movement | 5.6% |\n| Market Average Movement | 6.5% |\n| 10% most volatile stocks in US Market | 17.3% |\n| 10% least volatile stocks in US Market | 3.0% |\nStable Share Price: PSX has not had significant price volatility in the past 3 months compared to the US market.\nVolatility Over Time: PSX's weekly volatility (4%) has been stable over the past year.\nAbout the Company\n| Founded | Employees | CEO | Website |\n|---|---|---|---|\n| 1875 | 13,200 | Mark Lashier | www.phillips66.com |\nPhillips 66 operates as an energy manufacturing and logistics company in the United States, the United Kingdom, Germany, and internationally. It operates through five segments: Midstream, Chemicals, Refining, Marketing and Specialties (M&S), and Renewable Fuels. The Midstream segment transports crude oil and other feedstocks; delivers refined petroleum products to market; provides terminaling and storage services for crude oil and refined petroleum products; gathers, processes, transports, and markets natural gas; transports, fractionates, markets, and exports natural gas liquids.\nPhillips 66 Fundamentals Summary\n| PSX fundamental statistics | |\n|---|---|\n| Market cap | US$53.59b |\n| Earnings (TTM) | US$1.71b |\n| Revenue (TTM) | US$132.97b |\nIs PSX overvalued?\nSee Fair Value and valuation analysisEarnings & Revenue\n| PSX income statement (TTM) | |\n|---|---|\n| Revenue | US$132.97b |\n| Cost of Revenue | US$119.69b |\n| Gross Profit | US$13.28b |\n| Other Expenses | US$11.57b |\n| Earnings | US$1.71b |\nLast Reported Earnings\nJun 30, 2025\nNext Earnings Date\nn/a\n| Earnings per share (EPS) | 4.23 |\n| Gross Margin | 9.99% |\n| Net Profit Margin | 1.28% |\n| Debt/Equity Ratio | 73.1% |\nHow did PSX perform over the long term?\nSee historical performance and comparisonDividends\nDoes PSX pay a reliable dividends?\nSee PSX dividend history and benchmarks| Phillips 66 dividend dates | |\n|---|---|\n| Ex Dividend Date | Aug 19 2025 |\n| Dividend Pay Date | Sep 02 2025 |\n| Days until Ex dividend | 10 days |\n| Days until Dividend pay date | 4 days |\nDoes PSX pay a reliable dividends?\nSee PSX dividend history and benchmarksCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/28 07:41 |\n| End of Day Share Price | 2025/08/27 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nPhillips 66 is covered by 36 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| William Selesky | Argus Research Company |\n| Yim Cheng | Barclays |\n| Theresa Chen | Barclays |"
    },
    {
      "url": "https://simplywall.st/discover/investing-ideas/434426/us-transformative-artificial-intelligence-ai-healthcare-stocks/global?blueprint=4022332&utm_medium=finance_user&utm_campaign=investing-ideas&utm_source=yahoo&utm_content=ai-healthcare",
      "text": "Results\n27\nArtificial intelligence (AI) is set to transform healthcare by enhancing diagnostics, personalizing medicine, boosting operational efficiency, expanding remote care, and accelerating research. AI outperforms humans in detecting diseases like cancer from scans, tailors treatments using genetic and lifestyle data, and streamlines hospital workflows with tools like predictive analytics and automated transcription. It powers telemedicine, monitors chronic conditions in real-time, and speeds up drug discovery by analyzing vast datasets for insights into complex diseases. Despite challenges like data privacy, bias, and integration costs, AI\u2019s ability to improve accuracy, access, and affordability could save billions and extend lives, marking a seismic shift in healthcare delivery and outcomes.\n27 companies\nRakovina Therapeutics\nMarket Cap: US$10.6m\nA biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets.\nRKVT.F\nUS$0.38\n7D\n3.1%\n1Y\nn/a\nCosmo Pharmaceuticals\nMarket Cap: US$929.2m\nFocuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.\nCMOP.F\nUS$75.00\n7D\n0%\n1Y\n-21.1%\nGubra\nMarket Cap: US$5.8b\nA biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally.\nGUBR.F\nUS$60.15\n7D\n0%\n1Y\nn/a\nEvaxion\nMarket Cap: US$19.1m\nA clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.\nEVAX\nUS$3.03\n7D\n-2.3%\n1Y\n-81.8%\nImmunoPrecise Antibodies\nMarket Cap: US$126.9m\nOperates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company.\nIPA\nUS$2.65\n7D\n-8.3%\n1Y\n239.2%\nCareCloud\nMarket Cap: US$157.0m\nA healthcare information technology (IT) company, provides technology-enabled business solutions, Software-as-a-Service offerings, and related business services to healthcare providers and hospitals primarily in the United States.\nCCLD\nUS$3.71\n7D\n36.4%\n1Y\n35.4%\nGeneDx Holdings\nMarket Cap: US$3.6b\nA genomics company, provides genetic testing services.\nWGS\nUS$129.19\n7D\n7.4%\n1Y\n307.7%\nSpectral AI\nMarket Cap: US$54.8m\nAn artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States.\nMDAI\nUS$2.10\n7D\n2.9%\n1Y\n42.9%\nWELL Health Technologies\nMarket Cap: US$1.2b\nOperates as a practitioner-focused digital healthcare company in Canada, the United States, and internationally.\nWHTC.F\nUS$3.49\n7D\n0.6%\n1Y\n4.2%\nRevenio Group Oyj\nMarket Cap: US$641.1m\nProvides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally.\nREVX.F\nUS$31.47\n7D\n0%\n1Y\nn/a\nRadNet\nMarket Cap: US$5.5b\nProvides outpatient diagnostic imaging services in the United States and internationally.\nRDNT\nUS$71.29\n7D\n3.9%\n1Y\n10.2%\nSimulations Plus\nMarket Cap: US$281.2m\nDevelops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide.\nSLP\nUS$14.36\n7D\n2.3%\n1Y\n-60.2%\nCeriBell\nMarket Cap: US$420.2m\nOperates as a medical technology company focuses on transforming the diagnosis and management of patients with serious neurological conditions in the United States.\nCBLL\nUS$11.60\n7D\n0.2%\n1Y\nn/a\nNano-X Imaging\nMarket Cap: US$253.8m\nDevelops a commercial-grade tomographic imaging device with a digital X-ray source.\nNNOX\nUS$3.94\n7D\n0.9%\n1Y\n-36.9%\nGuardant Health\nMarket Cap: US$7.9b\nA precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.\nGH\nUS$63.50\n7D\n3.6%\n1Y\n144.9%\nPerimeter Medical Imaging AI\nMarket Cap: US$22.3m\nA medical technology company, provides advanced imaging solutions to address unmet medical needs.\nPYNK.F\nUS$0.15\n7D\n-7.2%\n1Y\n-32.7%\nHeartSciences\nMarket Cap: US$12.6m\nA medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness.\nHSCS\nUS$3.38\n7D\n-9.0%\n1Y\n4.3%\nOmniAb\nMarket Cap: US$197.5m\nA biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.\nOABI\nUS$1.61\n7D\n-10.6%\n1Y\n-62.3%\nNeuroOne Medical Technologies\nMarket Cap: US$38.5m\nA medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States.\nNMTC\nUS$0.75\n7D\n-0.2%\n1Y\n-2.6%\nBioXcel Therapeutics\nMarket Cap: US$76.3m\nTogether with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.\nBTAI\nUS$3.96\n7D\n-21.4%\n1Y\n-59.1%\nXtalPi Holdings\nMarket Cap: US$41.3b\nAn investment holding company, engages in the provision of robotics and drug discovery solutions in Mainland China, the United States, and internationally.\nQNTP.F\nUS$1.33\n7D\n15.7%\n1Y\nn/a\nLantheus Holdings\nMarket Cap: US$3.8b\nDevelops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.\nLNTH\nUS$56.84\n7D\n1.2%\n1Y\n-48.2%\nAbsci\nMarket Cap: US$468.6m\nOperates as a data-first generative artificial intelligence (AI) drug creation company in the United States.\nABSI\nUS$2.55\n7D\n-0.4%\n1Y\n-40.7%\nAcarix\nMarket Cap: US$308.9m\nA medical device company, develops solutions for rapid AI-based coronary artery disease rule-out.\nACIX.F\nUS$0.029\n7D\n-21.9%\n1Y\n-10.6%\nHealwell AI\nMarket Cap: US$361.7m\nA healthcare artificial intelligence company, develops and commercializes clinical decision support systems in Canada, New Zealand, Australia, and the United Kingdom.\nHWAI.F\nUS$0.96\n7D\n-1.3%\n1Y\n-31.1%\nPersonalis\nMarket Cap: US$432.7m\nDevelops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.\nPSNL\nUS$4.78\n7D\n3.0%\n1Y\n-13.6%\nVeradigm\nMarket Cap: US$839.0m\nA healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally.\nMDRX\nUS$4.94\n7D\n1.9%\n1Y\n-50.1%"
    },
    {
      "url": "https://simplywall.st/company/id/15E05696-3826-44C3-B624-607CEF9CF46E/valuation?blueprint=4022332&utm_medium=finance_user&utm_campaign=conclusion&utm_source=yahoo",
      "text": "Is PSX undervalued compared to its fair value, analyst forecasts and its price relative to the market?\nValuation Score\n2/6\nValuation Score 2/6\nBelow Fair Value\nSignificantly Below Fair Value\nPrice-To-Earnings vs Peers\nPrice-To-Earnings vs Industry\nPrice-To-Earnings vs Fair Ratio\nAnalyst Forecast\nShare Price vs Fair Value\nWhat is the Fair Price of PSX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.\nDiscounted Cash Flow\nSimply Wall St\nUS$347.43\nFair Value\n61.8% undervalued intrinsic discount\n19\nNumber of Analysts\nBelow Fair Value: PSX ($132.62) is trading below our estimate of fair value ($347.43)\nSignificantly Below Fair Value: PSX is trading below fair value by more than 20%.\nKey Valuation Metric\nWhich metric is best to use when looking at relative valuation for PSX?\nKey metric: As PSX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.\nThe above table shows the Price to Earnings ratio for PSX. This is calculated by dividing PSX's market cap by their current\nearnings.\nWhat is PSX's PE Ratio?\nPE Ratio\n31.4x\nEarnings\nUS$1.71b\nMarket Cap\nUS$53.59b\nPSX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.\nPrice-To-Earnings vs Industry: PSX is expensive based on its Price-To-Earnings Ratio (31.4x) compared to the US Oil and Gas industry average (13.2x).\nPrice to Earnings Ratio vs Fair Ratio\nWhat is PSX's PE Ratio\ncompared to its\nFair PE Ratio?\nThis is the expected PE Ratio taking into\naccount the company's forecast earnings growth, profit margins\nand other risk factors.\nPSX PE Ratio vs Fair Ratio.\nFair Ratio\nCurrent PE Ratio\n31.4x\nFair PE Ratio\n20x\nPrice-To-Earnings vs Fair Ratio: PSX is expensive based on its Price-To-Earnings Ratio (31.4x) compared to the estimated Fair Price-To-Earnings Ratio (20x).\nAnalyst Price Targets\nWhat is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?\nThe above table shows the analyst PSX forecast and predictions for the stock price in 12 month\u2019s time.\nDate\nShare Price\nAverage 1Y Price Target\nDispersion\nHigh\nLow\n1Y Actual price\nAnalysts\nCurrent\nUS$132.62\nUS$136.00\n+2.55%\n5.90%\nUS$158.00\nUS$125.00\nn/a\n19\nAug \u201926\nUS$119.60\nUS$136.47\n+14.11%\n5.97%\nUS$158.00\nUS$125.00\nn/a\n19\nJul \u201926\nUS$123.15\nUS$130.11\n+5.65%\n8.02%\nUS$156.00\nUS$110.00\nn/a\n21\nJun \u201926\nUS$113.48\nUS$130.07\n+14.62%\n8.09%\nUS$153.00\nUS$110.00\nn/a\n20\nMay \u201926\nUS$103.46\nUS$129.27\n+24.95%\n8.10%\nUS$149.00\nUS$106.00\nn/a\n20\nApr \u201926\nUS$124.35\nUS$139.44\n+12.14%\n7.35%\nUS$162.00\nUS$124.43\nn/a\n19\nMar \u201926\nUS$129.69\nUS$137.18\n+5.78%\n8.11%\nUS$162.00\nUS$115.00\nn/a\n19\nFeb \u201926\nUS$117.87\nUS$137.29\n+16.48%\n8.11%\nUS$162.00\nUS$115.00\nn/a\n19\nJan \u201926\nUS$113.93\nUS$140.75\n+23.54%\n8.36%\nUS$161.00\nUS$120.00\nn/a\n18\nDec \u201925\nUS$133.98\nUS$141.95\n+5.95%\n8.13%\nUS$167.00\nUS$122.00\nn/a\n18\nNov \u201925\nUS$120.01\nUS$143.23\n+19.35%\n7.89%\nUS$167.00\nUS$122.00\nn/a\n18\nOct \u201925\nUS$132.99\nUS$145.71\n+9.57%\n9.30%\nUS$182.00\nUS$122.00\nn/a\n17\nSep \u201925\nUS$140.31\nUS$153.08\n+9.10%\n8.24%\nUS$176.00\nUS$122.00\nn/a\n17\nAug \u201925\nUS$140.95\nUS$152.55\n+8.23%\n8.66%\nUS$176.00\nUS$122.00\nUS$119.60\n17\nJul \u201925\nUS$140.93\nUS$157.20\n+11.54%\n9.46%\nUS$191.00\nUS$122.00\nUS$123.15\n17\nJun \u201925\nUS$142.11\nUS$162.66\n+14.46%\n8.44%\nUS$191.00\nUS$122.00\nUS$113.48\n18\nMay \u201925\nUS$140.21\nUS$165.29\n+17.89%\n8.95%\nUS$191.00\nUS$125.00\nUS$103.46\n19\nApr \u201925\nUS$163.34\nUS$159.29\n-2.48%\n8.74%\nUS$179.00\nUS$125.00\nUS$124.35\n19\nMar \u201925\nUS$144.20\nUS$150.40\n+4.30%\n7.39%\nUS$169.00\nUS$125.00\nUS$129.69\n20\nFeb \u201925\nUS$145.55\nUS$145.17\n-0.26%\n8.84%\nUS$166.00\nUS$119.00\nUS$117.87\n20\nJan \u201925\nUS$133.14\nUS$135.39\n+1.69%\n7.54%\nUS$151.00\nUS$116.00\nUS$113.93\n19\nDec \u201924\nUS$129.70\nUS$130.52\n+0.63%\n6.40%\nUS$146.00\nUS$116.00\nUS$133.98\n17\nNov \u201924\nUS$116.09\nUS$130.64\n+12.53%\n6.49%\nUS$146.00\nUS$116.00\nUS$120.01\n17\nOct \u201924\nUS$120.15\nUS$131.11\n+9.12%\n6.41%\nUS$144.00\nUS$115.00\nUS$132.99\n16\nSep \u201924\nUS$117.17\nUS$127.05\n+8.43%\n5.44%\nUS$141.00\nUS$115.00\nUS$140.31\n16\nAug \u201924\nUS$112.11\nUS$120.12\n+7.14%\n7.01%\nUS$132.00\nUS$101.00\nUS$140.95\n17\nAnalystConsensusTarget\nConsensus Narrative from 19 Analysts\nUS$136.00\nFair Value\n2.5% undervalued intrinsic discount\n19\nNumber of Analysts\nAnalyst Forecast: Target price is less than 20% higher than the current share price.\nDiscover undervalued companies\n7D\n1Y\n7D\n1Y\n7D\n1Y\nCompany Analysis and Financial Data Status\nData\nLast Updated (UTC time)\nCompany Analysis\n2025/08/28 07:41\nEnd of Day Share Price\n2025/08/27 00:00\nEarnings\n2025/06/30\nAnnual Earnings\n2024/12/31\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nPhillips 66 is covered by 36 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day."
    },
    {
      "url": "https://simplywall.st/company/id/15E05696-3826-44C3-B624-607CEF9CF46E/past?blueprint=4022332&amp;utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo",
      "text": "Phillips 66 Past Earnings Performance\nPast criteria checks 2/6\nPhillips 66 has been growing earnings at an average annual rate of 30.4%, while the Oil and Gas industry saw earnings growing at 31.6% annually. Revenues have been growing at an average rate of 12.8% per year. Phillips 66's return on equity is 6.4%, and it has net margins of 1.3%.\nKey information\n30.36%\nEarnings growth rate\n31.42%\nEPS growth rate\n| Oil and Gas Industry Growth | 33.67% |\n| Revenue growth rate | 12.81% |\n| Return on equity | 6.39% |\n| Net Margin | 1.28% |\n| Last Earnings Update | 30 Jun 2025 |\nRecent past performance updates\nRecent updates\nPhillips 66: The Trajectory Is Improving\nAug 15Phillips 66 (NYSE:PSX) Might Be Having Difficulty Using Its Capital Effectively\nAug 14Phillips 66's (NYSE:PSX) Shareholders Will Receive A Bigger Dividend Than Last Year\nMay 06Weak Statutory Earnings May Not Tell The Whole Story For Phillips 66 (NYSE:PSX)\nMay 05With A 26% Price Drop For Phillips 66 (NYSE:PSX) You'll Still Get What You Pay For\nApr 09room for higher margins\nIndustry Position: Phillips 66 is a major player in the energy sector, particularly in refining, marketing, and transportation. Analysts often look at the company's ability to capitalize on operationaElliott Management Applies Pressure With Phillips 66 Board Fight\nMar 26Phillips 66: Ignore Elliott Management\nFeb 25Phillips 66 Just Missed Earnings - But Analysts Have Updated Their Models\nFeb 04Philips 66: Refining Hurts Q4, But Long-Term Value Remains\nFeb 01Phillips 66 Makes An Intelligent Acquisition Of EPIC NGL\nJan 13Phillips 66: Bottom Fishing At The Bottom Of The Refining Cycle (Rating Upgrade)\nDec 25Phillips 66: Refiners Are 'Deer In The Headlights' Of Canadian Import Tariffs\nDec 07Phillips 66: 3.4% Yield, Consistent Dividend Growth, Cheap\nOct 24Phillips 66 Is Expanding Past Its Refining Roots\nOct 18Are Investors Undervaluing Phillips 66 (NYSE:PSX) By 44%?\nOct 17Strategically Envisioning A Greener Future Through Innovative Energy Solutions And Financial Resilience\nTransition to producing renewable fuels at the Rodeo Renewable Energy Complex aims to meet growing demand for environmentally friendly energy options.These 4 Measures Indicate That Phillips 66 (NYSE:PSX) Is Using Debt Extensively\nSep 16The Value Of Phillips 66's Midstream Assets Shine Bright In 2024\nAug 01Phillips 66: Sell-Off Creates Opportunity, Given Likely Q2 Acceleration (Rating Upgrade)\nJul 12Phillips 66: Turnaround Still Very Much A Work In Progress\nApr 29Revenue & Expenses Breakdown\nHow Phillips 66 makes and spends money. Based on latest reported earnings, on an LTM basis.\nEarnings and Revenue History\n| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |\n|---|---|---|---|---|\n| 30 Jun 25 | 132,966 | 1,708 | 2,806 | 0 |\n| 31 Mar 25 | 137,772 | 1,846 | 2,776 | 0 |\n| 31 Dec 24 | 143,153 | 2,107 | 2,814 | 0 |\n| 30 Sep 24 | 147,738 | 3,358 | 2,961 | 0 |\n| 30 Jun 24 | 151,853 | 5,110 | 2,221 | 0 |\n| 31 Mar 24 | 148,814 | 5,792 | 2,309 | 0 |\n| 31 Dec 23 | 147,399 | 7,004 | 2,310 | 0 |\n| 30 Sep 23 | 149,408 | 7,629 | 2,497 | 0 |\n| 30 Jun 23 | 154,720 | 10,922 | 2,445 | 0 |\n| 31 Mar 23 | 168,207 | 12,392 | 2,293 | 0 |\n| 31 Dec 22 | 169,990 | 11,014 | 1,990 | 0 |\n| 30 Sep 22 | 162,315 | 10,403 | 2,017 | 0 |\n| 30 Jun 22 | 147,603 | 5,416 | 1,824 | 0 |\n| 31 Mar 22 | 126,028 | 2,543 | 1,769 | 0 |\n| 31 Dec 21 | 111,476 | 1,306 | 1,744 | 0 |\n| 30 Sep 21 | 95,242 | -506 | 1,697 | 0 |\n| 30 Jun 21 | 80,948 | -1,708 | 1,657 | 0 |\n| 31 Mar 21 | 64,881 | -2,142 | 1,633 | 0 |\n| 31 Dec 20 | 64,129 | -3,983 | 1,544 | 0 |\n| 30 Sep 20 | 76,863 | -2,707 | 1,603 | 0 |\n| 30 Jun 20 | 88,148 | -1,196 | 1,635 | 0 |\n| 31 Mar 20 | 105,083 | 369 | 1,634 | 0 |\n| 31 Dec 19 | 107,293 | 3,070 | 1,681 | 0 |\n| 30 Sep 19 | 107,330 | 4,573 | 1,609 | 0 |\n| 30 Jun 19 | 109,884 | 5,354 | 1,633 | 0 |\n| 31 Mar 19 | 110,994 | 5,270 | 1,657 | 0 |\n| 31 Dec 18 | 111,492 | 5,589 | 1,677 | 0 |\n| 30 Sep 18 | 108,719 | 6,547 | 1,695 | 0 |\n| 30 Jun 18 | 101,182 | 5,878 | 1,690 | 0 |\n| 31 Mar 18 | 93,037 | 5,088 | 1,697 | 0 |\n| 31 Dec 17 | 89,300 | 5,100 | 1,695 | 0 |\n| 30 Sep 17 | 83,177 | 2,066 | 1,678 | 0 |\n| 30 Jun 17 | 79,209 | 1,753 | 1,654 | 0 |\n| 31 Mar 17 | 76,725 | 1,699 | 1,636 | 0 |\n| 31 Dec 16 | 70,898 | 1,549 | 1,638 | 0 |\n| 30 Sep 16 | 69,143 | 2,036 | 1,651 | 0 |\n| 30 Jun 16 | 73,139 | 3,103 | 1,677 | 0 |\n| 31 Mar 16 | 79,837 | 3,620 | 1,662 | 0 |\n| 31 Dec 15 | 85,228 | 4,221 | 1,670 | 0 |\n| 30 Sep 15 | 98,055 | 4,717 | 1,685 | 0 |\n| 30 Jun 15 | 112,412 | 4,319 | 1,649 | 0 |\n| 31 Mar 15 | 129,169 | 4,169 | 1,655 | 0 |\n| 31 Dec 14 | 146,514 | 4,049 | 1,663 | 0 |\n| 30 Sep 14 | 154,640 | 3,711 | 1,649 | 0 |\nQuality Earnings: PSX has high quality earnings.\nGrowing Profit Margin: PSX's current net profit margins (1.3%) are lower than last year (3.4%).\nFree Cash Flow vs Earnings Analysis\nPast Earnings Growth Analysis\nEarnings Trend: PSX has become profitable over the past 5 years, growing earnings by 30.4% per year.\nAccelerating Growth: PSX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.\nEarnings vs Industry: PSX had negative earnings growth (-66.6%) over the past year, making it difficult to compare to the Oil and Gas industry average (-13.9%).\nReturn on Equity\nHigh ROE: PSX's Return on Equity (6.4%) is considered low.\nReturn on Assets\nReturn on Capital Employed\nDiscover strong past performing companies\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/28 07:41 |\n| End of Day Share Price | 2025/08/27 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nPhillips 66 is covered by 36 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| William Selesky | Argus Research Company |\n| Yim Cheng | Barclays |\n| Theresa Chen | Barclays |"
    }
  ],
  "argos_summary": "Phillips\u202f66 shares have risen 17\u202f% in the last three months, but the company\u2019s current ROE of 6.4\u202f% is well below the oil\u2011and\u2011gas industry average of 11\u202f%.  Despite the low ROE, the firm has delivered 30\u202f% annual earnings growth over five years and analysts project a 22.5\u202f% earnings CAGR and a 16.8\u202f% ROE in three years, driven by refining, midstream and renewable\u2011fuel expansion.  The stock trades at $132.62 versus a fair\u2011value estimate of $347.43, implying a 61\u202f% intrinsic discount, while a 3.4\u202f% dividend yield and upcoming earnings releases are key catalysts.  The company\u2019s debt\u2011heavy balance sheet and potential regulatory impacts on refining margins remain risks.",
  "argos_id": "HZN21YA3N"
}